Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases
  • 18
    May

Anagenesis Biotechnologies Announces Strategic Research Agreement with Boehringer Ingelheim to discover drugs for chronic Muscle Diseases
  • Posted by:
  • Anagenesis
  • May 18th, 2017

Illkirch Graffenstaden, France – May 18, 2017 – Anagenesis Biotechnologies announced today a strategic research agreement with Boehringer Ingelheim, which grants Boehringer Ingelheim an exclusive access to Anagenesis’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology for chronic muscle diseases.
BI-ANAG PR May 18 2017

BI – Anagenesis CP_18 mai 2017

Contact Us Get in touch!

Latest News Latest News

  • Pr. Olivier Pourquié, Co-founder of Anagenesis By Anagenesis
    June 17th
    Professor Olivier Pourquié, Co-founder of Anagenesis, publication in “Development” on June 15, 2020. https://dev.biologists.org/content/early/2020/06/12/dev.187344
  • Pr. Olivier Pourquié, co-founder By Anagenesis
    June 17th
    Professor Olivier Pourquié, co-founder of Anagenesis was nominated by the US National Academy of Sciences, on April 27, 2020. http://www.nasonline.org/news-and-multimedia/news/2020-nas-election.html
  • Anagenesis announces Professor Gordon Keller, joining the Board of Directors By Anagenesis
    September 18th
    Anagenesis announced that Professor Gordon Keller is joining its Board of Directors. Professor Keller is currently Director of the McEwen Stem Cell Institue at the University Health Network and Senior Scientist at the...